source
- Celldex halts development of mast cell antibody after Phase 2 failure in prurigo nodularisCelldex announced it will discontinue the clinical program for its mast cell‑targeting monoclonal antibody aimed at treating prurigo nodularis, a chronic itchy‑skin condition. The decision follows…
- Biotech deal activity picks up in Q2 2026, signaling recovery after summer slumpThe biotech sector experienced a sharp decline in confidence last summer, leading to a slowdown in financing and partnership activity. New data show that in the second quarter of 2026, dealmaking…